Devitol is commonly used for managing symptoms across key gynecological domains, and may assist with distressing manifestations of several conditions. It is applied across domains where additional symptomatic support is needed, and used when symptoms become noticeable and create interference with a patient's daily stability.

This medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and used in situations involving certain distressing symptoms. Devitol is commonly used to help with symptom clusters associated with absent or irregular menstrual cycles, abnormal uterine bleeding, endometriosis, and concerns related to endometrial overgrowth.

“It is relevant when supportive symptom management is appropriate and supports the patient during difficult episodes by easing distress.”

It is often used when symptoms intensify and supportive relief is needed, and is relevant for easing symptoms that create noticeable physiological strain during phases when symptoms become more noticeable.

---

Quick Fact: Support for Heightened Symptoms Devitol supports patients during episodes of heightened discomfort and is relevant for easing symptoms associated with episodic or fluctuating gynecological manifestations.

Regulatory References

1. NIH MedlinePlus overview on its uses

Who Can and Cannot Use Devitol (Dihydrotachysterol)?

Official regulatory guidelines strictly define the eligible population for Devitol, a medication containing Dihydrotachysterol. Eligibility is based on a patient's existing metabolic state, age, and organ function, as defined in government prescribing information.

---

Contraindications and Restrictions

Classification	Population Status
Absolute Contraindicated Use	Devitol is contraindicated in patients with pre-existing Hypercalcaemia (high blood calcium levels), Hypervitaminosis D (Vitamin D toxicity), Metastatic Calcification, or a known Hypersensitivity to the drug or its components.
Conditional Use (Caution Required)	Use requires caution in patients with impaired Renal Function (kidney disease), a history of Kidney Stones (Renal Calculi), or pre-existing Heart Disease and Arteriosclerosis, due to the heightened risk associated with hypercalcaemia in these groups.

---

Age and Reproductive Status

Population Group	Eligibility Rule
Pediatric Patients	Use is established but must be highly monitored in infants due to increased sensitivity; dosage is individualized.
Pregnancy	Use is restricted and permitted only if the regulatory-determined potential benefit justifies the potential risk to the fetus.
Nursing Mothers	Use is restricted, and caution must be exercised. Infant serum calcium monitoring may be required.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Devitol (Dihydrotachysterol) around additive effects on calcium balance and altered drug exposure.

Documented Pharmacodynamic Interactions

Co-administration with agents that also elevate calcium levels may lead to a heightened risk of hypercalcemia and related adverse events. This includes concurrent use with Thiazide Diuretics and other Vitamin D Analogs. The risk of serious adverse effects, specifically ventricular arrhythmias, is increased when Devitol is combined with Cardiac Glycosides (like Digoxin) due to Devitol-induced hypercalcemia. For patients with hypoparathyroidism, this hypercalcemia risk with Thiazide Diuretics is specifically noted.

Exposure and Absorption Restrictions

Interactions that alter the concentration of Devitol include the use of Bile Acid Sequestrants (e.g., Cholestyramine), which are documented to decrease the serum concentration of Devitol by interfering with its absorption. Consequently, official labeling may specify administration timing rules, such as taking Devitol at least four hours prior to the sequestrant. Corticosteroids also decrease the therapeutic efficacy of Devitol. Additionally, Devitol may increase the serum concentration of Aluminum Hydroxide, a component in certain antacids.

Non-Medicinal Product Interactions

High dietary intake of calcium or phosphate may require adjustment to avoid cumulative toxic effects. Regulatory warnings also state that consumption of Grapefruit or Grapefruit Juice may officially alter the blood levels and effects of Dihydrotachysterol.

Devitol acts as an agonist for the Vitamin D Receptor (VDR), an intracellular nuclear receptor expressed across various tissues. Upon ligand binding, the Devitol-VDR complex translocates to the nucleus where it dimerizes with the Retinoid X Receptor (RXR), forming a VDR-RXR heterodimer. This complex functions as a transcription factor, binding to specific DNA sequences known as Vitamin D Response Elements (VDREs) to modulate the transcription rate of target genes.

This gene expression modulation manifests in two primary cascades: first, the upregulation of genes encoding proteins responsible for intestinal calcium transport; and second, the direct inhibition of pre-pro-PTH gene transcription within the parathyroid glands, leading to a reduction in parathyroid hormone (PTH) levels. The combined effects primarily result in the modulation of mineral homeostasis pathways through tightly regulated biochemical processes, influencing bone mineralization and calcium handling.

Official Administration Guidelines for Devitol

Devitol (Dihydrotachysterol) is administered exclusively via the oral route in available forms, which include tablets, capsules, and a liquid solution. The medicine’s usage is defined by a strictly individualized dosage regimen that requires continuous oversight and is tied directly to the patient’s biochemical status.

Administration typically follows a two-phase protocol: an initial loading phase and a long-term maintenance phase. The initial adult dose commonly starts in the range of 0.8 mg to 2.4 mg once daily for a few days. This is followed by a transition to a lower, tailored maintenance dose, which often falls between 0.2 mg and 1.0 mg once daily. The final therapeutic dose is meticulously determined by regular laboratory monitoring of serum calcium levels.

The dosing frequency is generally once daily, though some maintenance schedules may prescribe use on alternate days. Dose adjustments are not made frequently; instead, they are performed only as directed by laboratory results, with adjustments typically occurring at four to eight-week intervals. Devitol may be taken with or without food, offering flexibility in daily timing. However, the liquid solution requires a calibrated dropper for precise measurement, and patients using this form must ensure accuracy when administering the dose. A critical procedural condition is the requirement for concurrent and adequate daily calcium supplementation. Specific dosage rules are also provided for use in pediatric populations. If a daily dose is missed, it should be taken when remembered unless it is nearly time for the next dose, in which case the missed dose must be skipped to avoid a double dose.

Research Evidence / Overview of Studies for Devitol

Evidence for Use in Chronic Hypoparathyroidism

Research regarding Devitol was studied for its use in individuals with chronic low calcium levels (hypocalcemia) due to insufficient Parathyroid Hormone (PTH). Studies included both adults and children, primarily utilizing observational cohort designs and older comparative controlled trials. Researchers monitored outcomes related to systemic mineral imbalance, focusing on the patterns of blood calcium balance observed. These studies reported measurements showing shifts in serum calcium levels during the conventional management regimen. However, many foundational studies are older with modest sample sizes, and follow-up durations were often limited, meaning long-term clinical outcomes are not fully established in contemporary trials.

---

Evidence for Use in Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

Research examined Devitol in individuals with Chronic Kidney Disease (CKD) who experience mineral and bone disorders, involving Randomized Controlled Trials (RCTs). These studies included populations with impaired kidney function and tracked biochemical markers such as Parathyroid Hormone (PTH), serum calcium, and phosphate levels. Research examined shifts in PTH concentration associated with Devitol use. The evidence level for this indication is described as Moderate. The existing research relies heavily on surrogate biochemical endpoints rather than long-term patient-reported outcomes, and data for certain vulnerable groups remain insufficient.

---

Research on Rickets and Osteomalacia (Specific Forms)

The evidence base is derived from historical case series and clinical observation reports for patients whose specific metabolic defects complicate the processing of standard Vitamin D. Historical studies reported measurements regarding the biochemical levels of calcium and phosphate and associated radiographic findings of bone structure. Findings described the course of clinical symptoms alongside treatment, confirming its classification as a Vitamin D analog. Comparative evidence is lacking against standard modern treatments for common nutritional deficiency states.

---

Long-Term Data and Research Gaps

Research has monitored the duration of effect across long periods through extended case series, documenting the duration of monitoring in these extended patient cohorts. This long-term data relies more on observational patterns than on dedicated, controlled trials. The current evidence landscape describes several areas where data are still emerging, including long-term cardiovascular impact and fracture risk data, which are primarily based on observational patterns rather than controlled studies.

Key Studies & References Hypoparathyroidism: Aetiology, diagnosis, and management (Clinical Review)

Common questions about Devitol (FAQ)

---

Q: How quickly does Devitol usually start working?

Official information related to Dihydrotachysterol indicates it has a relatively rapid onset of action, with effects beginning as early as two hours after administration. This rapid action distinguishes it from some other related compounds. However, achieving the required stable blood calcium levels typically requires consistent, ongoing treatment according to the prescribing professional’s directions.

---

Q: Why is Devitol only available by prescription?

Devitol is a prescription-only medicine primarily because of its potent effect on the body's mineral balance. Official regulatory documents emphasize the risk of severe toxicity, such as dangerously high blood calcium levels (hypercalcemia). Due to these serious risks, the drug requires continuous laboratory monitoring and strictly individualized dosing, which necessitates professional medical oversight.

---

Q: Can Devitol affect the results of blood tests?

While Devitol does not typically interfere with the laboratory process of blood tests, its intended function is to change certain values. Official prescribing information states that the drug's activity is directly reflected in the serum calcium level, which is regularly monitored. The maintenance of this level within the correct therapeutic range is required as part of the overall regimen.

---

Q: Can older adults use Devitol safely?

Regulatory labeling indicates that dosage selection for older adults should be approached with caution. This is due to the potential for a greater frequency of decreased organ function, such as in the liver, kidneys, or heart, which are more common in this population. A healthcare professional may need to take these factors into account when determining the appropriate starting regimen.

---

Q: Can taking Devitol cause weight changes?

Official regulatory information mentions that weight loss is a documented symptom associated with the early stages of hypercalcemia, which is the main safety concern with Devitol. This is an indirect effect related to the overall toxicity of elevated calcium levels rather than a direct side effect of the medicine itself. Patients should review any unexpected weight changes with their prescribing professional.

---

Q: How is Devitol removed from the body?

According to official pharmacokinetic information, Devitol's active ingredient, Dihydrotachysterol, and its breakdown products (metabolites) are not considered dialyzable. This means they cannot be effectively removed from the body using kidney dialysis procedures. The body's natural metabolic processes manage the compound's elimination over time.

---

Q: Can Devitol cause skin reactions or rashes?

Official safety information states that Devitol can potentially cause hives, which is a type of skin reaction. Hives are described as a possible sign of a hypersensitivity or allergic reaction to the medication. The appearance of hives or other severe skin issues is noted as a sign that requires immediate medical attention.

---

Q: Can Devitol be split in half?

Official administration guidelines do not provide instructions for splitting or crushing Devitol tablets or capsules. The liquid solution form of the medicine is the one specifically labeled for precise measurement using a calibrated dropper. Altering the solid dosage form is not recommended unless explicitly permitted by the prescribing professional.

---

Q: Does Devitol have a 'black box warning' in the US?

A Boxed Warning (often called a 'black box warning') is a specific requirement from the FDA for drugs with very serious safety concerns. While official labeling for Devitol includes serious warnings regarding the risk of hypercalcemia, Dihydrotachysterol does not currently carry a formal Boxed Warning in the US product information.

---

Q: Can people with liver disease take Devitol?

Official regulatory information notes that Dihydrotachysterol requires a process called hepatic hydroxylation (chemical change in the liver) to become fully active. Therefore, hepatic impairment or liver disease can potentially alter the therapeutic activity and concentration of the drug in the body. Dosage is determined by a prescribing professional who accounts for any known liver condition.

Storage and Disposal Conditions for Devitol

Devitol (Dihydrotachysterol) must be stored under specific regulatory conditions to maintain its effectiveness. The medication should be kept at room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from heat, direct light, and moisture. It is prohibited to freeze the product or store it in damp locations like the bathroom. Always keep the medicine in its original container and out of the reach and sight of children.

Disposal Instructions

Unused or expired Devitol should be disposed of using a drug take-back program. If this is not an option, the medicine must be mixed with an undesirable substance (such as kitty litter or coffee grounds), sealed in a bag, and then placed in the household trash. Do not flush Devitol down a sink or toilet.